Selinexor for Treatment of Light Chain Amyloidosis With Relapsed/Refractory Disease

EARLY_PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

December 31, 2021

Primary Completion Date

June 30, 2023

Study Completion Date

June 30, 2024

Conditions
AmyloidAmyloidosisAL Amyloidosis
Interventions
DRUG

Selinexor

Selinexor will be given orally at a dose of 60mg once weekly on the first day of the week (day 1, 8, 15, and 22) for Cycle 1 and up to Cycle 12.

DRUG

Dexamethasone

Dexamethasone will be given orally at a dose of 20mg, if tolerated, or at a reduced dose if required, 30 to 60 minutes prior to selinexor for first 2 days of each week only (days 1, 2, 8, 9, 15, 16, 22, and 23 of each cycle).

Trial Locations (1)

10065

Weill Cornell Medicine - Multiple Myeloma Center, New York

Sponsors
All Listed Sponsors
collaborator

Karyopharm Therapeutics Inc

INDUSTRY

lead

Weill Medical College of Cornell University

OTHER